Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:CRSP News 19 October 2025 - 24 January 2026

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics shares slipped 0.5% to $60.51 in premarket trading Friday after CEO Samarth Kulkarni sold 90,000 shares for about $5.2 million under a preset plan, an SEC filing showed. The stock had surged 11.1% Thursday on heavy volume. Options trading spiked, with focus on April $90 calls. Bank of America trimmed its price target to $89 but kept a Buy rating.
23 January 2026
··
CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next

CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next

CRISPR Therapeutics shares fell 4.5% to $53.84 Friday ahead of its Monday presentation at the J.P. Morgan Healthcare Conference. Investors are focused on updates for Casgevy’s commercial rollout, patient starts, and payer coverage. The therapy, approved for sickle cell disease, is co-developed with Vertex, which records product revenue. Traders await signals on 2026 projections and revenue ramp-up.
12 January 2026
··
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
2 January 2026
······
CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

NEW YORK, Dec. 27, 2025, 4:58 p.m. ET — Market closed (U.S. equities are shut for the weekend) CRISPR Therapeutics AG (NASDAQ: CRSP) heads into the final trading stretch of 2025 with investors balancing two forces that often define biotech stocks: headline-driven momentum and long-duration fundamental risk. The stock finished the most recent regular session (Friday, Dec. 26) at $55.08, down 2.87%, after trading between $56.54 and $53.76. In after-hours trading, CRSP was last shown around $55.24 late Friday evening. StockAnalysis That Friday move came against a holiday-thinned tape on Wall Street. Reuters described the broader market session as light-volume
27 December 2025
··
CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

Updated: December 4, 2025 Key takeaways CRISPR Therapeutics stock today: price, volatility and positioning As of pre‑market trading on December 4, 2025, CRISPR Therapeutics AG (NASDAQ: CRSP) is changing hands at roughly $56, just above Wednesday’s close of $55.99, after jumping 8.5% in the last regular session. stockinvest.us+1 Over the past 12 months, CRSP has traded between about $30.04 and $78.48, leaving today’s price squarely in the middle of its 52‑week range. stockinvest.us A few quick stats: Technically, services like StockInvest.us classify CRSP as a “hold/accumulate” with a wide expected three‑month range (~$43–$64), while Intellectia’s model calls it a “Strong
4 December 2025
·
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Current News Stock Price and Market Activity CRSP is trading around the mid-$60s ahead of Monday’s open. By Reuters (Nov 2) it was ~$64.04 (up +4.86% on the day) Reuters. (Nasdaq closes on Oct 31 showed ~$63.99 Reuters.) Over the past month CRSP has gained roughly 17% Genengnews, boosted by recent data releases. For example, a 3-day rally in mid-Oct lifted CRSP ~5% after the SyNTase/CTX460 results were announced Genengnews. Technical indicators are mixed: the 14-day RSI is ~50 (neutral) and the MACD is slightly negative Investing. Shorter moving averages (5/10/20-day around $63–$63.8) are giving buy signals Investing, but the
2 November 2025
······
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency (AATD). The data – highlighted at the ESGCT conference – showed that a single dose of CTX460 delivered by lipid nanoparticles corrected the disease-causing mutation in >90% of liver cells and boosted functional AAT protein ~5-fold in animal models globenewswire.com. “The preclinical results demonstrate the potential of CTX460, developed using our novel SyNTase editing platform, to correct the mutation with precision and efficiency,” said CRISPR CMO
19 October 2025
···

Stock Market Today

Financial services stocks rally as XLF jumps, Dow hits 50,000 — what to watch next week

Financial services stocks rally as XLF jumps, Dow hits 50,000 — what to watch next week

7 February 2026
U.S. financial stocks rose Friday, with the XLF fund up 1.8% and the Dow closing above 50,000 for the first time, gaining 2.47%. Goldman Sachs jumped 4.3%, JPMorgan 3.9%, and Citigroup 6.0%. The Federal Reserve held rates steady, and San Francisco Fed President Mary Daly signaled possible cuts this year. Investors await January jobs and inflation data next week.
Data Center Stocks Surge Into the Weekend: Digital Realty, Equinix and Vertiv Set Up a Big Week Ahead

Data Center Stocks Surge Into the Weekend: Digital Realty, Equinix and Vertiv Set Up a Big Week Ahead

7 February 2026
Digital Realty, Equinix, and Vertiv shares surged Friday, with Vertiv up 10% and Digital Realty rising 4.1%, as investors rotated back into AI-linked data center stocks. The move followed Amazon’s $200 billion and Alphabet’s $175–185 billion 2026 capex targets. Digital Realty set 2026 core FFO guidance at $7.90 to $8.00 per share. Wall Street ended the week broadly higher, led by chipmakers.
Go toTop